阿奇霉素联合双黄连颗粒对支原体肺炎患儿免疫功能及肺表面活性物质相关蛋白-D水平的影响

Effect of azithromycin combined with Shuanghuanglian granule on immune function and pulmonary surfactant-associated protein D level in children with mycoplasma pneumonia

目的探讨阿奇霉素联合双黄连颗粒对支原体肺炎患儿免疫功能及肺表面活性物质相关蛋白-D (SP-D)水平的影响。方法选取2017年7月-2018年6月浙江大学医学院附属第二医院长兴院区收治的182例支原体肺炎患儿为研究对象,采用随机数字表进行分组,每组各91例。对照组患儿给予阿奇霉素治疗;在此基础上,观察组患儿加用双黄连颗粒治疗。比较两组患儿临床疗效、治疗期间不良反应发生率,治疗前后T淋巴细胞亚群(CD3^+、CD4^+、CD8^+)比例、血清炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6 (IL-6)、超敏C-反应蛋白(hs-CRP)]及SP-D水平。结果观察组患儿总有效率(97. 80%)显著高于对照组(87. 91%)(P<0. 05)。治疗前,两组患儿T淋巴细胞亚群比例、血清炎性因子及SP-D水平比较差异均无统计学意义(均P>0. 05);治疗后,两组患儿T淋巴细胞亚群比例、血清炎性因子及SP-D水平比较差异均有统计学意义(均P<0. 05)。治疗期间,两组患儿不良反应发生率比较差异均无统计学意义(P>0. 05)。结论阿奇霉素联合双黄连颗粒可有效治疗小儿支原体肺炎,提高患儿免疫功能,降低炎症因子水平,改善临床症状,安全可靠。

Objective To explore the effect of azithromycin combined with Shuanghuanglian granule on immune function and pulmonary surfactant-associated protein D( SP-D) level in children with mycoplasma pneumonia. Methods A total of 182 children with mycoplasma pneumonia treated in Changxing Department,the Second Affiliated Hospital of Medical College of Zhejiang University from July 2017 to June 2018 were selected and divided into two groups according to random number table,91 children in each group. The children in control group were treated by azithromycin;the children in observation group were treated by azithromycin combined with Shuanghuanglian granule.The clinical effects,the incidence rates of adverse reactions in the course of treatment,the proportions of T lymphocyte subsets( CD3^+,CD4^+,CD8^+),serum inflammatory factors [tumor necrosis factor-α( TNF-α),interleukin-6( IL-6),high-sensitivity C-reactive protein( hs-CRP) ] and SP-D levels in the two groups were compared. Results The total effective rate in observation group( 97. 80%) was statistically significantly higher than that in control group( 87. 91%)( P< 0. 05). Before treatment,there was no statistically significant difference in the proportions of T lymphocyte subsets,serum inflammatory factors and SP-D levels between the two groups( P>0. 05). After treatment,there were statistically significant differences in the proportions of T lymphocyte subsets,serum inflammatory factors and SPD levels between the two groups( P<0. 05). There was no statistically significant difference in the incidence rate of adverse reactions in the course of treatment between the two groups( P>0. 05). Conclusion Azithromycin combined with Shuanghuanglian granule can effectively treat children with mycoplasma pneumonia,improve immune function,reduce the levels of inflammatory factors,improve clinical symptoms,the therapy is safe and reliable.